Skip to main content
. 2020 May 30;3(2):126–145. doi: 10.1093/abt/tbaa011

Table 2.

BsAbs under clinical development in China by Chinese companies as of May 2020 [78]

Identifier Drug Company Targets BsAb format and platform Indication Phase
CTR20171194 M802 YZYBio HER2 × CD3 scFv-Fab IgG; YBODY HER2-positive advanced solid tumor I
CTR20181212 M701 YZYBio EpCAM × CD3 scFv-Fab IgG; YBODY Malignant ascites I
CTR20182027 AK104 Akeso PD-1 × CTLA-4 IgG-(scFv)2; Tetrabody Advanced solid tumor and advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma Ib/II
CTR20190205 A-319 Generon CD19 × CD3 (scFv)2-Fab; ITAB Refractory or relapsed B cell lymphoma I
CTR20190853 KN026 Alphamab HER2 × HER2 Hetero H, common LC IgG; CRIB Advanced gastric and gastroesophageal junction carcinoma with overexpression and low expression of HER2 II
CTR20182404 SHR-1701 Hengrui PDL1 × TGFβ Antibody-receptor fusion Metastatic castration resistant prostate cancer I
CTR20181823 Advanced malignant solid tumor
CTR20181760 MBS301 Mabworks HER2 × HER2 Fab-arm exchange HER2 high expression of locally advanced, inflammatory or early breast cancer, metastatic breast cancer, metastatic gastric cancer, etc. I
CTR20190427 KN046 Alphamab PD-L1 × CTLA-4 Hetero VHH-Fc; CRIB Advanced unresectable or metastatic esophageal squamous cell carcinoma II
CTR20190197 Triple negative breast cancer II
CTR20190195 Non-small-cell lung cancer II
CTR20181996 Chinese advanced solid tumor and lymphoma subjects I
CTR20190241 EMB-01 Epimab EGFR × c-MET F(ab)2-IgG; FIT-Ig Advanced/metastatic solid tumors, including but not limited to non-small-cell lung cancer, colorectal cancer (no RAS-positive mutation), gastric cancer, liver cancer, and other solid tumors I
CTR20190340 IBI318 Innovent PD-1 × PD-L1 Fab-arm exchange Advanced malignant tumor I
CTR20190888 ES101 Elpiscience PD-L1 × CD137 Tandem VHH-Fc Advanced solid tumor I
CTR20191955 K193 Lvzhu CD19 × CD3 F(ab)2-(scFv)2-Fc B-cell lymphoma I
CTR20191677 IBI315 Innovent HER2 × PD-1 Fab-arm exchange Advanced malignant tumor I
CTR20192612 IMM0306 ImmuneOnco CD47 × CD20 Antibody-receptor fusion Lymphoma I
CTR20192299 HX009 HanxBio CD47 × PD-1 Antibody-receptor fusion Malignant tumors such as liver cancer, stomach cancer, and colorectal cancer I
CTR20200502 SI-B001 Biokin HER3 × EGFR IgG-(scFv)2 Locally advanced or metastatic epithelial tumor, including esophageal squamous cell carcinoma, lung squamous cell carcinoma, triple negative breast cancer, head and neck squamous cell carcinoma, colorectal cancer, etc. I
CTR20200175 IBI322 Innovent PD-L1 × CD47 Not available Solid tumors and hematological tumors I
CTR20200549 MGD013 ZLAB PD-1 × LAG-3 DART Advanced liver cancer (including hepatocellular carcinoma and intrahepatic cholangiocarcinoma) I
CTR20200289 Advanced gastric adenocarcinoma or adenocarcinoma at the gastroesophageal junction with previous treatment failed I
CXSL1900112 SI-B003 Biokin Undisclosed Not available Undisclosed IND
CXSL1900131 KD6001 Kanda Undisclosed Not available Advanced malignant tumor IND
CXSL1900150 PM8001 Biotheus Undisclosed Not available Advanced solid tumor I